Avidity Biosciences Inc (NASDAQ:RNA) has a beta value of 1.01 and has seen 2.46 million shares traded in the last trading session. The company, currently valued at $3.21B, closed the last trade at $26.74 per share which meant it lost -$2.78 on the day or -9.42% during that session. The RNA stock price is -109.42% off its 52-week high price of $56.00 and 19.37% above the 52-week low of $21.56. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.66 million shares traded. The 3-month trading volume is 1.38 million shares.
The consensus among analysts is that Avidity Biosciences Inc (RNA) is Buy stock at the moment, with a recommendation rating of 1.07. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.88.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Sporting -9.42% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RNA stock price touched $26.74 or saw a rise of 19.29%. Year-to-date, Avidity Biosciences Inc shares have moved -8.05%, while the 5-day performance has seen it change -16.70%. Over the past 30 days, the shares of Avidity Biosciences Inc (NASDAQ:RNA) have changed -8.49%. Short interest in the company has seen 16.13 million shares shorted with days to cover at 12.47.
Wall Street analysts have a consensus price target for the stock at $54.5, which means that the shares’ value could jump 50.94% from current levels. The projected low price target is $50.0 while the price target rests at a high of $59.0. In that case, then, we find that the current price level is -120.64% off the targeted high while a plunge would see the stock gain -86.99% from current levels.
Avidity Biosciences Inc (RNA) estimates and forecasts
The company’s shares have lost -36.83% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -23.41%.
8 analysts offering their estimates for the company have set an average revenue estimate of 2.62M for the current quarter. 8 have an estimated revenue figure of 2.51M for the next ending quarter. Year-ago sales stood 3.54M and 2.04M respectively for this quarter and the next, and analysts expect sales will shrink by -25.92% for the current quarter and -23.41% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -34.37% over the past 5 years. Earnings growth for 2025 is a modest -32.24% while over the next 5 years, the company’s earnings are expected to increase by 0.06%.
RNA Dividends
Avidity Biosciences Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
Insiders own 5.03% of the company shares, while shares held by institutions stand at 107.34% with a share float percentage of 113.02%. Investors are also buoyed by the number of investors in a company, with Avidity Biosciences Inc having a total of 330.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 16.16 million shares worth more than $660.1 million. As of 2024-06-30, FMR LLC held 15.1121% of shares outstanding.
The other major institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, with the holding of over 10.92 million shares as of 2024-06-30. The firm’s total holdings are worth over $445.94 million and represent 12.5173% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are T. Rowe Price New Horizons Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 3.68% shares in the company for having 4.43 shares of worth $118.4 million while later fund manager owns 3.5 shares of worth $93.64 million as of Dec 31, 2024 , which makes it owner of about 2.91% of company’s outstanding stock.
